Fed. Circ. Mulls PTAB Ruling's Effect On Liquidia Drug Launch
A Federal Circuit panel on Tuesday grappled with whether a Delaware judge was correct to hold that Liquidia Technologies could launch a hypertension drug after a United Therapeutics patent the company...To view the full article, register now.
Already a subscriber? Click here to view full article